Jospiten

Lercanidipine Hydrochloride, the active ingredient in Jospiten, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adults with hypertension.

GNH USA supplies Jospiten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is a dihydropyridine calcium‑channel blocker used in the management of high blood pressure.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic readings, especially in older adults. - Hypertension in the elderly: provides once‑daily blood pressure control with a favorable tolerability profile.

Lercanidipine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, usually limited to the face and neck. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence, particularly in patients with pre‑existing coronary disease. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, pruritus, or angioedema requiring discontinuation.

Before initiating therapy with Lercanidipine Hydrochloride, certain safety considerations should be observed.

- Blood pressure monitoring: check baseline and periodic readings to assess efficacy and avoid excessive hypotension. - Liver function assessment: evaluate hepatic enzymes in patients with known liver disease. - Concomitant antihypertensives: adjust doses when used with other blood‑pressure‑lowering agents. - Elderly patients: start at the lowest effective dose and monitor for edema. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Other calcium‑channel blockers (e.g., amlodipine): additive vasodilatory effect leading to excessive blood pressure drop. - Grapefruit juice: inhibits metabolism, raising drug concentrations.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑dihydropyridine calcium blockers (e.g., verapamil): may increase risk of bradycardia. - Diuretics: combined use can potentiate orthostatic hypotension.